Study: Generic biologics not much cheaper

May 03, 2007

A U.S. study has determined generic versions of a class of medicines called "biologics" would not be significantly cheaper than brand-name drugs.

Biologics are drugs, vaccines and other medicines produced by living cells in controlled circumstances, but there is no established process for the review and approval of generic versions of biologic products, such as insulin.

"Congress and the (U.S. Food and Drug Administration) are currently addressing this issue and developing a process for the oversight of generic biologics, partially in hopes of generating significant cost savings for consumers and insurers," said Duke University Professor Kevin Schulman. "However, our research indicates that any savings to be expected from the addition of generic biologics to the marketplace will be significantly less than the savings generally available from generic pharmaceuticals."

The study, which also included Professors David Ridley and Henry Grabowski as authors, is to be published in the journal Managerial and Decision Economics.

Copyright 2007 by United Press International

Explore further: Prescription drug monitoring programs offer multiple benefits

Related Stories

A small fish caught in a big fuss

Feb 08, 2011

When Peter Moyle began studying an obscure little Northern California fish in the early 1970s, he had no inkling of the role it would come to play in the state.

Recommended for you

FDA clears drug for leading form of cystic fibrosis

Jul 02, 2015

Federal health officials have approved a new combination drug for the most common form of cystic fibrosis, the debilitating inherited disease that causes internal mucus buildup, lung infections and early death. But it will ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.